October 2013

Gilead Alberta expands research and manufacturing facility in Canada

Wednesday, October 30, 2013

Gilead Alberta, a fully integrated research and manufacturing facility of Gilead Sciences Canada, has announced a $47 million expansion of its research and manufacturing facility in Edmonton, Alberta. The expansion will create more than 80 full-time positions at Gilead Alberta and increase the size of the facility by 45,000 square feet to create new laboratory and research space. 

[Read More]

Langland, CISCRP show participant impact on clinical trials

Wednesday, October 30, 2013

Langland, a healthcare advertising agency, has launched “Speak Out, But Speak Smart,” an online communication guide for clinical trial participants. Developed in collaboration with CISCRP, the web site encourages discussions while showing how sharing certain information can have unforeseen consequences: for example, psychosomatic side effects resulting from the knowledge of another participant’s adverse event.

[Read More]

Stemline Therapeutics, Leukemia & Lymphoma Society collaborate

Wednesday, October 30, 2013

Stemline Therapeutics, a clinical-stage biopharmaceutical company developing novel oncology therapeutics, and The Leukemia & Lymphoma Society (LLS) are collaborating to accelerate the development of SL-401 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematological disorder with both leukemic and lymphomatous characteristics.

[Read More]